Related Experiment Video

Updated: Oct 26, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

815

Plasma convalescent decrease mortality in COVID-19 patients: a systematic review and meta-analysis

A Yuwono Soeroto1, A Purwiga, A Alam

  • 1Division of Pulmonology and Critical Care Medicine, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin Hospital, Bandung, Indonesia. aysoeroto@yahoo.co.id.

European Review for Medical and Pharmacological Sciences
|August 2, 2021
PubMed

Insights

Convalescent plasma (CP) effectively reduced mortality in severe and critical COVID-19 patients. This meta-analysis found CP use associated with decreased mortality, with generally tolerable adverse effects observed.

Area of Science:

  • Infectious Diseases
  • Immunology
  • Critical Care Medicine

Background:

  • COVID-19 poses a significant global health threat, particularly for severe and critical cases.
  • Convalescent plasma (CP) emerged as a potential therapeutic option for mitigating COVID-19 severity.
  • Understanding the efficacy of CP in reducing mortality is crucial for clinical decision-making.

Purpose of the Study:

  • To systematically evaluate the role of Convalescent Plasma (CP) in reducing mortality among COVID-19 patients.
  • To synthesize evidence from comparative studies investigating CP treatment for COVID-19.

Main Methods:

  • A comprehensive literature search was performed across PubMed, Embase, Medrxiv, and Google Scholar (April-December 2020).
  • Included studies were comparative (retrospective or prospective) with a control group, focusing on mortality as the primary outcome.
  • Eighteen studies involving 5658 patients (2092 treated with CP) were included in this meta-analysis.

Main Results:

  • Convalescent plasma (CP) use was significantly associated with decreased mortality in COVID-19 patients (OR = 0.64; 95% CI 0.49 to 0.84; p<0.001).
  • The meta-analysis demonstrated low statistical heterogeneity (I² = 27.62%).
  • Adverse events were reported in a small number of patients, with no fatal cases linked to CP treatment.

Conclusions:

  • Convalescent plasma (CP) is an effective therapeutic intervention for reducing mortality in severe and critical COVID-19 cases.
  • CP treatment demonstrates a favorable safety profile with tolerable adverse effects.
  • The findings support the use of CP as part of the management strategy for severe COVID-19.
Abstract

More Related Videos

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses03:53

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses

Published on: November 10, 2023

1.5K
An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient07:16

An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient

Published on: November 30, 2022

3.8K

Related Concept Videos

Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
521
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
76
Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
534
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
1.1K
Pneumonia V: Nursing management and Prevention01:30

Pneumonia V: Nursing management and Prevention

Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
2.8K
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
461